Giant leiomyosarcoma: A case report

Taylan Senol a, Ilker Kahramanoglu b,*, Bahar Muezzinoglu c, Izzet Yucesoy a

a Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Kocaeli University Medical School, Kocaeli, Turkey
b Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Istanbul University Cerrahpasa Medical School, Istanbul, Turkey
c Department of Pathology, Kocaeli University Medical School, Kocaeli, Turkey

A R T I C L E   I N F O

Article history:
Received 17 November 2015
Received in revised form 3 December 2015
Accepted 19 December 2015
Available online 28 December 2015

Keywords:
Leiomyosarcoma
Size
Leiomyoma

A B S T R A C T

INTRODUCTION: Uterine leiomyosarcoma is a rare uterine malignancy. Most of the patients lack symptoms or present with a rapidly enlarging pelvic mass.

PRESENTATION OF CASE: We report on a very large leiomyosarcoma in a woman presenting with a 3 months history of rapidly growing abdominal mass and fatigue. Laparotomy was performed and diagnosis was confirmed by pathologic and histologic analysis. Patient refused chemotheraphy after surgery and died from recurrence at 4th postoperative month.

DISCUSSION: Uterine leiomyosarcomas may follow a rapid clinical course with a doubling time of four weeks. There is no reliable method to distinguish uterine sarcoma from benign leiomyomas preoperatively.

CONCLUSION: This case represents the largest leiomyosarcoma reported in the literature.

© 2015 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Postoperative histopathological evaluation showed large areas of necrosis and increased mitotic activity. Tumor cells were spindle shaped, pleomorphic and had moderate to severe atypia. There was no evidence of lymph node metastasis and peritoneal involvement. Immunohistochemical study with antibodies against p16, p53 and Ki-67 were performed and 64% of cells were positive for Ki-67 (Fig. 4).

Chemotherapy was recommended to patient, but she refused the treatment. Metastatic tumors appeared on intestinal serosa and abdominal wall after surgery. Her condition deteriorated rapidly and patient died from recurrence of LMS at 4th postoperative month.

Written informed consent was obtained from the patient shortly after the surgery for publication of this case report.

3. Discussion

Uterine LMSs are rare uterine malignancies [1]. However, the incidence of sarcoma is 1–2% in postmenopausal women [8]. LMS is an aggressive tumor associated with a high risk of recurrence and death, regardless of stage at presentation and differ
from other types of endometrial cancer [9]. Currently, there is no reliable method to differentiate uterine leiomyosarcoma from benign leiomyomas preoperatively. The diagnosis of leiomyosarcoma should be suspected when severe pelvic pain accompanies a pelvic tumor, in a postmenopausal woman particularly [9].

Uterine leiomyosarcomas may follow a rapid clinical course with a doubling time of four weeks [8]. Our patient had noticed the growth of abdomen which had been carrying 57 kg of sarcoma, just 3 months before the surgery.

LMS, like all other endometrial cancers, is surgically staged. Surgical staging should include a hysterectomy and a BSO with the resection of any visible metastatic disease. 60% of the women with LMS present with the disease limited to the uterus upon first diagnosis [5]. Cure rates of these patients range from 20 to 60%, depending on the success of the primary resection [7]. Several case series support the role of primary surgery [10,11]. Surgical cytoreduction is associated with progression-free survival (PFS); however, it is not associated with overall survival (OS). As such, the morbidity of surgery must be weighed against the improvement in PFS [12]. In the largest series involving 46 patients with LMS, a complete cytoreduction was significantly associated with disease-free survival ($p = 0.03$) [11]. Ovarian preservation can be considered in premenopausal patients with early-stage LMS of the uterus. In a study of 341 women less than 50 years old who were stage I or II LMS at diagnosis, no difference was found in the five-year disease-free survival between those who did and did not undergo a BSO [13]. We performed a BSO in this case as the patient had postmenopausal status.

However, sarcomas are aggressive tumors with a high risk of local and distant relapse even in completely resected tumors [2,14]. Patients with even International Federation of Gynecology and Obstetrics (FIGO) stages I and II LMS have a very high risk of recurrence. Survival after recurrence is poor. In one study, the 5-year survival rate for women with 1988 FIGO stage I LMS (tumour limited to the uterus) was only 51%, and for patients with stage II LMS (tumour in uterus and cervix), the 5-year survival rate was 25% [15]. The relapse rate is approximately 70% for stages I and II. The site of metastasis or recurrence is often distant due to the haematogenous spread into the lungs or liver [5].

Radiation therapy appears to have little benefit in the treatment of early-stage LMS. A retrospective review from the Surveillance, Epidemiology and End Results database of women with stage I/II LMS demonstrated no survival benefit from adjuvant radiation therapy [16]. There are few prospective data on the utility of chemotherapy for stage I/II LMS. A prospective study has demonstrated that the combination chemotherapy of gemcitabine and docetaxel followed by doxorubicin offers a survival benefit to uterine leiomyosarcoma patients [17]. Our patient chose to reject chemotherapy despite our recommendation.

To the best of our knowledge, no case describing a similar size of leiomyosarcoma has been described in the English literature.

Conflict of interest

We declare that we have no conflict of interest.

Funding

None.

References

[1] S.E. Brooks, M. Zhan, T. Cote, C.R. Baquet, Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999, Gynecol. Oncol. 83 (2002) 204–208.
[2] K. Kaur, P. Kaur, A. Kaur, A. Singla, Uterine leiomyosarcoma: a case report, J. Midlife Health 5 (4) (2014) 202–204.
[3] G. Zivanovic, M. Leitao, A. Lasonos, M. Lindsay, Q. Jacks, N. Abu Rustum, Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems, J. Clin. Oncol. 27 (2009) 2066–2072.
[4] H.K. Sait, N.M. Anfinan, M.E. El Sayed, S.S. Alkhayyat, A.T. Ghanem, R.M. Abayazid, et al., Uterine sarcoma. Clinico-pathological characteristics and outcome, Saudi Med. J. 35 (10) (2014) 1215–1222.
[5] S. Sgae, K. Yamashita, S. Ishioka, Y. Nishioka, K. Terasawa, M. Momi, et al., Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan, Oncology 67 (2004) 33.
[6] S. Leibsohn, G. D’Ablaing, D. Mishell Jr., J. Schlaerth, Leiomyosarcoma in series of hysterectomies performed for presumed uterine leiomyomas, Am. J. Obstet. Gynecol. 162 (1990) 968–974.
[7] A. Gadducci, S. Cosio, A. Romanini, A. Genazzani, The management of patients with uterine sarcoma: a debated clinical challenge, Crit. Rev. Oncol. Hematol. 65 (2008) 129–142.
[8] V.S. Vellanki, M. Rao, C.B. Sunkavalvi, R.N. Chinamotu, S. Kaja, A rare case of uterine leiomyosarcoma, J. Med. Case Rep. 4 (2010) 222.
[9] E. D’Angelo, J. Prat, Uterine sarcomas: a review, Gynecol. Oncol. 116 (2010) 131.
[10] T.A. Dinh, E.A. Oliva, A.F. Fuller Jr., et al., The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990–1999) at the Massachusetts General Hospital, Gynecol. Oncol. 92 (2004) 648.
[11] J.Y. Park, D.Y. Kim, D.S. Suh, et al., Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989–2007, J. Cancer Res. Clin. Oncol. 134 (2008) 1277.
[12] M.M. Leitao Jr., O. Zivanovic, D.S. Chi, et al., Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis, Gynecol. Oncol. 125 (2012) 409–413.
[13] B.S. Kapp, J.Y. Shin, J.K. Chan, Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy, Cancer 112 (2008) 820.
[14] L. Ramondetta, Uterine sarcomas, in: P. Eifel, M.D. Anderson (Eds.), Cancer Care Series, Gynecologic Cancer, Springer, New York, 2006, p. 125.
[15] V.M. Abeler, O. Royne, S. Thoresen, H.E. Danielsen, J.M. Nesland, G.B. Kristensen, Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients, Histopathology 54 (2009) 355–364.
[16] J.D. Wright, V.E. Seshan, M. Shah, et al., The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma, Am. J. Obstet. Gynecol. 199 (2008) e1–e8.
[17] M. Hensley, J. Wathen, R. Maki, D.M. Anrojo, D.A. Sutton, D.A. Priebe, et al., Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005), Cancer 119 (2013) 1555–1561.

Consent

Written informed consent form was obtained from the patient for publication of this case report.

Authors contribution

TS: Data collection, literature search.J.K.: Writing the paper, data analysis.B.M.: Data collection.I.Y.: Study concept and review.

Guarantor

Ilker Kahramanoglu.

Open Access

This article is published Open Access at sciencedirect.com. It is distributed under the IJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.